Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Univax Biologics Inc.

(UNVX)

Charles Noland of Dakin Securities reiterated a "buy" under $10 and a "strong buy" under

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE